Exchange: NASDAQ·Updated 07:59 PM EST
CAPR logo

CAPR Capricor Therapeutics Inc

$9.53
$0.71
(6.93%)
Today
Closed $9.53
$0.0489
(0.51%)
After Hours
Reported EarningsNov 10
Mkt Cap$554.09M
Vol3.67M

About CAPR

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
75

Extremely Bullish Sentiment

How do you feel about CAPR?

LineBacker04
$CAPR Part-2 1. CAPR analysis based on data So, following these principles, I did a deep dive into all previous FDA evaluations where a drug was controversially voted against followed by an amendment and an extension, and the data shows a clear trend. a) In April 25, 2016 an FDA panel voted 3–7 against Sarepta's Exondys 51 which, following an extension was approved in September 2016. b) In March 2022, Amylyx's Relyvrio was voted down 4-6 by an AdCom panel and subsequently approved after an extension c) Biogen's Aduhelm also went through the same trajectory - voted 0-10 against and approved after a 6 month extension In all cases where the FDA accepted an extension (meaning there's something meaningful beyond what was discussed in the AdCom) the applications were APPROVED with one caveat - the only thing that tripped up an application was major safety concerns. I ran the analysis on a much larger data set - but the ones closest to our application were really the three discussed above.
1
109
LineBacker04
$CAPR Part-5 3. Checkmate and Latham I did another deep dive on Capricor’s retention of Latham & Watkins LLP and Checkmate Government Relations. This represents a dual-track Washington strategy: pairing the premier Tier-1 FDA legal escalation team with one of the most well-connected political lobbying firms in the Trump administration. What the data tells me about this pairing is a deck heavily stacked towards an approval. I went through the track record for both and their success rate is quite simply STUNNING. 4. Expectations for the Green Day. a) At this point I'm near certain we will get an approval - the real question is the label. b) The short-position on this is simply staggering and setup for a massive squeeze - this is just not sustainable c) Expecting approval next week with a possible announcement on Monday 11/23 -> PMR negotiations is what could cause delay
2
102
LineBacker04
$CAPR Part-4 In most situations, those negotiations run close to or past the PDUFA clock, and the agency simply holds the approval until the terms are finalized a) Mandatory Pre-Approval Sign-Off: Under statutory rules (including accelerated approval under 21 CFR 601.41 and safety mandates under Section 505(o)(3)), the FDA cannot issue an approval letter until the sponsor formally commits to specific PMR trial milestones—such as final protocol submission, trial completion, and final report dates. I believe (based on data) that this is where $CAPR is and this is why Linda is "BULLISH" on Cardio data. b) Rejections Don't Wait on PMRs: If the FDA intends to issue a Complete Response Letter (CRL), it never negotiates PMRs. In all cases on rejections, the response typically comes a few weeks earlier than the PDUFA data. We're now past the data where most rejections hit and the fact that we're pushing into the final week before PDUFA is highly bullish.
2
98
Erez1979
$CAPR Stepping away from the charts and price targets for a second—just wanted to share something . I’ve volunteered at a day center for children with Duchenne Muscular Dystrophy (DMD) and other neuromuscular/degenerative conditions, and honestly, it puts everything in life into perspective. As hard as I tried to bring smiles to their faces that day, I came home broken and in tears—it shook me for an entire week. Beyond any trade, I truly pray and hope this therapy—and every other treatment that can help these kids—gets approved and brought to them as fast as possible. May God bless these children and their families with health, strength, and hope. 🙏❤️
61
Jacko27
$CAPR SMMT holds 0 weight on my thesis. None. INO was the CBER rare disease precedent. An open label, single arm Phase 1/2 study in 32 adults, with no randomization and no placebo or active comparator. Not a CDER company that failed its OS endpoint against an established SOC in a lung cancer. Accelerated approval is the bare minimum here.
2
50
Stormfury66
$CAPR FDA states continued commitment to APPROVE rare disease drugs . This happened Friday after hours . Deramiocel drug with CAPR should be next in the coming days GLTA
1
65
MrsBelfort
$CAPR Putting the cart before the horse a little bit but go pull up REPL's chart post approval. I cashed out my calls and bought more stock while shorts were screaming it was going to dip below $10 post approval. It is right now at 21.89, touching $23.54 earlier. I am still holding my shares. So if and when the approval is granted for Deramiocel, resist the temptation to sell too soon and use the block button for your mental peace. 1 more week!
50
Erez1979
$CAPR CAPR vs. $SMMT — Why Today’s SMMT CRL Has Zero Bearing on CAPR: Seeing some panic comparing $CAPR to $SMMT’s CRL today—here is why they are completely different setups: • $SMMT filed despite missing statistical significance on Overall Survival (OS) in HARMONi, hoping the FDA would bend and approve on PFS alone. The FDA stood firm on OS. • $CAPR did the exact opposite: it removed the cardiac endpoint that struggled at AdCom and narrowed its amended BLA specifically to upper limb function (PUL) in ages 9+—the exact primary endpoint where Phase 3 HOPE-3 achieved full statistical significance, backed by 2-year OLE data and active labeling discussions. Different division (CBER vs. Oncology), different mechanism, and $CAPR is filing on a statistically hit endpoint, not asking for a pass on a missed one.
39
RaymondBabbitt
$CAPR Well, here we are. No later than one week from today, we should have the answer many of us have been anxiously waiting for - the FDA’s response regarding CAPR’s Deramiocel trial. I find myself experiencing an array of emotions, and I suspect I’m not alone. There’s excitement, hope, nervousness, uncertainty, etc. As I previously posted, none of us knows what the FDA’s response will be. We have studied the data, read the opinions, listen to the arguments, and convinced ourselves that we have a pretty good idea of what’s coming. We’ve made our decisions with available information that doesn’t give us absolute certainty. So, with the upcoming decision, I hope we can give one another a little understanding and respect. There’s no need for hostility or personal attacks. We’re all trying to figure this out in our own way. I recognize that my decision may be incorrect. Lastly, let’s not forget what’s at stake for the patients! 🙏🫶
36
dnfrs
$CAPR It is great to have a really brilliant guy on our side. is a national treasure! Deramiocel approval is a big deal but it will be followed by at least half a dozen very strong catalysts over the next few months! $90 on PUL approval with short squeeze + $20 more on PUL and Cardio approval + $30 more on CAPR solo marketer in US (doubles revenue) + $30 more on European/ROW partnership upfront +milestones + sale of Voucher for $200 million + + StealthX exosome therapeutics news! = about $170 January 15, 2027 Don't sell too early ! And Capricor has several more DMD drugs in the StealthX portfolio !
45
GreylockSec
$CAPR ...In regards to PDUFA's with an accepted 'major Amendment' (and I queried it over 10-year period), the odds in favor are pretty decent actually... Query: -When looking deeper at historical FDA Review cycles and historical decisions when there is a 'major Amendment' included in the review process over the last 10 years, approximately what percentage of those new amendments were crls and what percentage were new drug approvals ? A: - "Over the last decade, applications that receive a major amendment actually have a higher probability of receiving an approval at the end of that cycle than applications without an extension. Approximate Outcome Breakdown : Across Original BLAs over 10 years, roughly 12% to 23% of filed applications incur a major Amendment. When those extended cycles reach their revised PDUFA action date, the outcomes break down roughly as follows: Approvals (First-Cycle / Extended-Cycle): ~75% to 85% Complete Response Letters (CRLs): ~15% to 25% ..."
1
36
JeffSaves
$CAPR For anyone who sees Adam F’s post and cares or reads into them. I remember last December when Martin Shrkeli and another big name were hammering CAPR stock non stop. The day the positive news came out, Martin S got the call during his live stream, he was margin called and it’s speculated that he lost millions. CAPR went from 5$ a share to 40$ a share. Some of those people are paid to sway you. Let’s hope we can make them pay again.
32
BaxterCrewzc
$CAPR did anyone mention the fact that “From January 1, 2026, through November 10, 2026, the Company has not sold any shares under its at-the-market (ATM) program.” isn’t this very bullish? A biotech with a strong balance sheet, major catalyst approaching, and an untapped ATM
1
43
Learninandburnincash
$CAPR this is the first time I have felt extremely assured in approval. I would be completely shocked by a rejection, they would be going against pretty much the whole medical world to reject it at this point
41
dnfrs
$CAPR One poster ask me if I am serious about the Capricor share price reaching about $170 by January 15 ! The answer is yes ! Obviously it is all based on Deramiocel receiving full approval next week. And it is even more likely if it is for approval for both PUL and cardio. The American Heart Association Award clearly says it deserves the cardio approval! The next 4 catalysts can certainly occur in the next 2 months! * CAPR solo marketer in US (doubles revenue) * European and ROW partnership with upfront and milestones * StealthX news abut 3 or 4 new drugs entering clinic * Sale of Voucher for $200+ million. This just happened for another company in a 2 month period after a drug approval! Capricor cannot control the overall market (eg. Wars and Tariffs) but even in a rocky market investors should seek a safe harbor!
36
ObsOlet
$CAPR Quick Context on Today’s SEC Filing (Schedule 13G/A): Don’t let today’s filing date (Nov 13) confuse you: November 13 is simply the official statutory SEC deadline (45 days after quarter-end) for institutional investors to report their portfolio changes from Q3 (as of September 30, 2026). This exit did not happen today right before the finish line. It was purely an internal risk-management move following the turbulence around the July AdCom and the August extension (Major Amendment)—at a time when uncertainty was at its peak. Here is everything that has happened since that September 30 cutoff, which the fund had no way of knowing at the time: WMS Congress, The PPMD webinar and the unified open letter from 28 leading DMD clinicians to the FDA urging approval. Winning the prestigious AHA Outstanding Research Award for the HOPE-3 cardiac data. And the Q3 Call & 10-Q): The fundamental setup today is completely different from what it was back then.
1
39
Stormfury66
$CAPR People SMMT has ZERO play on the upcoming FDA decision on CAPR . ZERO comparison . Opposite ends of the scientific spectrum . CAPR did a major amendment to their BLA & removed the cardio aspect as that was the sticking point with the Adcom & refined to the Upper Limb with both clinical and statistical evidence showed slowing of deterioration of skeletal muscle which is an improvement both sides agree upon . Very strong conviction FDA APPROVAL FOR UPPER LIMB IS COMING . Label expansion to include heart is still undecided at this time still in discussions . GLTA VERY BULLISH
29
Dash_Man
$CAPR Longs: we've spent months (or years) examining the clinical evidence, the FDA's statistical objections, the administrative record, and the market structure. We've arrived at a reasoned assessment, not a certainty. We don't need to win any argument with trolls. We need to wait seven days for the evidence that actually matters
41
ObsOlet
$CAPR My final takeaway from the Q3 call and my investment thesis heading into the final trading week before PDUFA are rock-solid on approval! Taken individually, any quote from CEO Linda Marbán (Nov 10) could be dismissed as standard executive diplomacy—combined, however, they paint a clear picture: confirming the application is in the “final stages of FDA review” with no further inspections expected shows key operational hurdles are behind them. Even more telling is her remark that they are “not disclosing label information at this point” while weighing whether cardiac data goes “in the label now or will be a future label expansion.” A publicly traded biotech CEO does not discuss a future label expansion 12 days before PDUFA unless initial approval is firmly within reach—the legal liability would be far too high. Everything points to final labeling alignment for initial approval based on PUL 2.0.
29
Oddisey
$CAPR Am Heavily stocked up and fully prepared to hold even long after approval💥 Block me if you have doubts, so I dont have to read your negativev whining.
29

Advertisement|Remove ads.